Axonics® to Participate in Piper Sandler Virtual Healthcare Conference

Rhea-AI Summary

Axonics, Inc. (Nasdaq: AXNX), a medical technology company, will participate in the Piper Sandler Virtual Healthcare Conference on December 1, 2021. A pre-recorded fireside chat featuring Axonics senior management will be available on November 22, 2021, at 10:00 AM ET. Axonics specializes in innovative treatments for bladder and bowel dysfunction, with its rechargeable sacral neuromodulation system and the Bulkamid^® urethral bulking agent. The company’s products are widely offered in the U.S. and Europe, providing solutions for millions affected by these conditions.

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the Piper Sandler Virtual Healthcare Conference on December 1, 2021.

In advance of the virtual conference, a pre-recorded fireside chat with Axonics senior management will be made available on Monday, November 22 at 10:00 AM Eastern Time. Interested parties may access the fireside chat by visiting the Axonics investor relations website.

About Axonics

Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. The company’s rechargeable sacral neuromodulation (SNM) system provides patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, Axonics’ best-in-class urethral bulking agent, Bulkamid^®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI).

Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 20 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005068/en/

Neil Bhalodkar

Investor Relations

949-336-5293

ir@axonics.com

Source: Axonics, Inc.

FAQ

When is Axonics participating in the Piper Sandler Virtual Healthcare Conference?

Axonics is scheduled to participate in the conference on December 1, 2021.

What is the date and time of the pre-recorded fireside chat by Axonics?

The pre-recorded fireside chat will be available on November 22, 2021, at 10:00 AM Eastern Time.

What products does Axonics offer for bladder and bowel dysfunction?

Axonics offers a rechargeable sacral neuromodulation system and the Bulkamid® urethral bulking agent for treating bladder and bowel dysfunction.

How many adults are affected by overactive bladder in the U.S. and Europe?

Approximately 87 million adults in the U.S. and Europe are affected by overactive bladder.

What is the estimated market for fecal incontinence concerning Axonics?

It is estimated that about 40 million adults in the U.S. and Europe suffer from fecal incontinence.

Where can I find more information about Axonics?

More information about Axonics can be found on their official website at www.axonics.com.